McGoon Michael D, Kane Garvan C
Pulmonary Hypertension Clinic, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clin Proc. 2009 Feb;84(2):191-207. doi: 10.4065/84.2.191.
Pulmonary arterial hypertension is a progressive, symptomatic, and ultimately fatal disorder for which substantial advances in treatment have been made during the past decade. Effective management requires timely recognition and accurate diagnosis of the disorder and appropriate selection among therapeutic alternatives. Despite progress in treatment, obstacles remain that impede the achievement of optimal outcomes. The current article provides an overview of the pathobiologic mechanisms of pulmonary arterial hypertension, including genetic substrates and molecular and cellular mechanisms, and describes the clinical manifestations and classification of pulmonary arterial hypertension. The article also reviews established approaches to evaluation and treatment, with emphasis on the appropriate application of calcium channel blockers, prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors. In addition, the authors discuss unresolved issues that may complicate patient management, such as the clinical importance of mild or exercise-related pulmonary arterial hypertension, and they identify avenues by which treatment may advance in the future through the use of combination treatment, outcomes assessment, and exploration of alternative pharmacologic strategies.
肺动脉高压是一种进行性、有症状且最终会致命的疾病,在过去十年中其治疗取得了重大进展。有效的管理需要及时识别和准确诊断该疾病,并在治疗方案中进行适当选择。尽管治疗取得了进展,但仍存在阻碍实现最佳治疗效果的障碍。本文概述了肺动脉高压的病理生物学机制,包括遗传基础以及分子和细胞机制,并描述了肺动脉高压的临床表现和分类。本文还回顾了既定的评估和治疗方法,重点是钙通道阻滞剂、前列环素类似物、内皮素受体拮抗剂和磷酸二酯酶5抑制剂的适当应用。此外,作者讨论了可能使患者管理复杂化的未解决问题,如轻度或与运动相关的肺动脉高压的临床重要性,并确定了未来通过联合治疗、疗效评估和探索替代药物策略可能推动治疗进展的途径。